Because HK2 silencing increased cell death induced by growth factor deprivation and because sorafenib, a multikinase inhibitor that inhibits both growth factor receptors and downstream kinases, is being used for HCC therapy, we examined the synergism between HK2 ablation and sorafenib. Here, HK2 is linked to hepatocellular carcinoma.